Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
US Army
Daiichi Sankyo
Julphar
UBS
Accenture
Cantor Fitzgerald
Chubb
Medtronic

Generated: August 20, 2018

DrugPatentWatch Database Preview

Schering Company Profile

« Back to Dashboard

Summary for Schering
International Patents:179
US Patents:6
Tradenames:64
Ingredients:56
NDAs:102
Patent Litigation for Schering: See patent lawsuits for Schering

Drugs and US Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering NOXAFIL posaconazole SUSPENSION;ORAL 022003-001 Sep 15, 2006 RX Yes Yes 6,958,337 ➤ Sign Up Y Y ➤ Sign Up
Schering METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride TABLET;ORAL 070598-001 Feb 2, 1987 DISCN No No ➤ Sign Up ➤ Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-001 Apr 6, 1987 DISCN No No ➤ Sign Up ➤ Sign Up
Schering NAQUA trichlormethiazide TABLET;ORAL 012265-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 5,968,902 ➤ Sign Up
Schering NORMODYNE labetalol hydrochloride TABLET;ORAL 018687-002 Aug 1, 1984 4,066,755 ➤ Sign Up
Schering EULEXIN flutamide CAPSULE;ORAL 018554-001 Jan 27, 1989 4,472,382 ➤ Sign Up
Schering NORMOZIDE hydrochlorothiazide; labetalol hydrochloride TABLET;ORAL 019046-004 Apr 6, 1987 4,066,755 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SCHERING drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2008-09-30
➤ Subscribe Injection 0.75 mg/mL, 100 mL vial ➤ Subscribe 2009-06-05
➤ Subscribe Delayed-release Tablets 100 mg ➤ Subscribe 2014-06-16
➤ Subscribe Injection 2 mg/mL, 100 mL vial ➤ Subscribe 2008-12-18
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2011-02-28
➤ Subscribe Injection 18 mg/mL, 16.7 mL vials ➤ Subscribe 2015-11-24

Non-Orange Book US Patents for Schering

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,693,626 Tetrahydrofuran antifungals ➤ Sign Up
5,714,490 Tetrahydrofuran antifungals ➤ Sign Up
5,703,236 Tetrahydrofuran antifungals ➤ Sign Up
5,703,079 Tetrahydrofuran antifungals ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Schering Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/008 United Kingdom ➤ Sign Up PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
216 Luxembourg ➤ Sign Up 91216, EXPIRES: 20191220
1214076/01 Switzerland ➤ Sign Up PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Queensland Health
Cipla
Fuji
Teva
Boehringer Ingelheim
Cantor Fitzgerald
Citi
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.